2023
Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini E. Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes? Hepatology 2023, 77: e184-e185. PMID: 36724446, DOI: 10.1097/hep.0000000000000312.Commentaries, Editorials and Letters
2016
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?
Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, Strazzabosco M, Belli LS. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? Journal Of Hepatology 2016, 66: 236-237. PMID: 27592303, DOI: 10.1016/j.jhep.2016.08.016.Peer-Reviewed Original Research